Effects of CD4 and CD8 T lymphocyte depletion on the course of histoplasmosis following pulmonary challenge

Medical Mycology

Volumn 41, Issue 3, 2003, Pages 189-197

  Schnizlein Bick, C ^a   Durkin, M ^a,c   Kohler, S ^b   Connolly, P ^a,c   LeMonte, A ^a,c   Garringer, T ^a,c   Goldberg, J ^a,c   Smedema, M ^a   Brizendine, E ^a   Wheat, L Joseph ^a,b,c  

^a INDIANA UNIVERSITY   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Histoplasmosis Reference Laboratory   (United States)

Author keywords

Animal model; Cytokine; Histoplasmosis; Immunosuppression

Indexed keywords

MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; FATALITY; FLOW CYTOMETRY; FUNGAL DEVELOPMENT; HISTOPATHOLOGY; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LUNG; LUNG INFECTION; LYMPH NODE; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PATHOGENESIS; SURVIVAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

AJELLOMYCES; AJELLOMYCES CAPSULATUS; ANIMALIA;

EID: 0042825987     PISSN: 13693786     EISSN: None     Source Type: Journal    
DOI: 10.1080/1369378031000137279     Document Type: Article

References (19)

1. Deepe Jr. GS, Bullock WE. Histoplasmosis: A granulomatous inflammatory response. In: Gallin JI, Goldstein IM, Snyderman R (eds). Inflammation: Basic Principals and Clinical Correlates. New York: Raven, 1988: 733-749.
2. Wheat LJ, Slama TG, Norton JA, et al. Risk factors for disseminated or fatal histoplasmosis. Ann Intern Med 1982; 96: 159-163.
3. Wheat LJ, Connolly-Stringfield PA, Baker RL, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: Clinical findings, diagnosis and treatment, and review of the literature. Medicine (Baltimore) 1990; 69: 361-374.
4. Wheat J, Hafner R, Korzun AH, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Med 1995; 98: 336-342.
5. Wheat J, MaWhinney S, Hafner R, et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. Am J Med 1997; 103: 223-232.
6. McKinsey DS, Spiegel RA, Hutwagner L, et al. Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: Incidence, risk factors, and pathophysiology. Clin Infect Dis 1997; 24: 1195-1203.
7. Wheat L. Histoplasmosis in the Acquired Immunodeficiency Syndrome. Current Topics in Medical Mycology 1996; 7: 7-18.
8. Sathapatayavongs B, Batteiger BE, Wheat LJ, Slama TG, Wass JL. Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983; 62: 263-270.
9. Procknow JJ, Page MI, Loosli CG. Early pathogenesis of experimental histoplasmosis. Arch Pathol 1960; 69: 413-426.
10. Fojtasek MF, Sherman MR, Garringer T, Blair R, Wheat LJ, Schnizlein-Bick CT. Local immunity in lung-associated lymph nodes in a murine model of pulmonary histoplasmosis. Infect Immun 1993; 61: 4607-4614.
11. Defaveri J, Graybill JR. Immunohistopathology of murine histoplasmosis during normal and hypersensitive conditions. Am Rev Respir Dis 1991; 144: 1366-1372.
12. Baughman RP, Kim CK, Vinegar A, Hendricks DE, Schmidt DJ, Bullock WE. The pathogenesis of experimental pulmonary histoplasmosis: Correlative studies of histopathology, bronchoalveolar lavage, and respiratory function. Am Rev Respir Dis 1986; 134: 771-776.
13. + T-cell clone. Infect Immun 1993; 61: 714-718.
14. Gomez AM, Bullock WE, Taylor CL, Deepe Jr. GS. Role of L3T4+ T cells in host defense against Histoplasma capsulatum. Infect Immun 1988; 56: 1685-1691.
15. Worsham PL, Goldman WE. Selection and characterization of ura5 mutants of Histoplasma capsulatum. Mol Gen Genet 1988; 214: 348-352.
16. Jeannings SR, Bonneau RH, Smith PM, Wolcott RM, Chervenak R. CD4-positive T lymphocytes are required for the generation of the primary but not the secondary CD8 positive cytolic T lymphocyte response to herpes simplex virusin C57BL/6 mice. Cell Immunol 1991; 133: 234-252.
17. Connolly P, Wheat LJ, Schnizlein-Bick C, et al. Comparison of a New Triazole, Posaconazole, with Itraconazole and Amphotericin B for Treatment of Histoplasmosis following Pulmonary Challenge in Immunocompromised Mice. Antimicrob Agents Chemother 2000; 44: 2604-2608.
18. + T cells in host resistance to systemic infection with Histoplasma capsulatum in mice. J Immunol 1994; 152: 3491-3500.
19. Allendoerfer R, Brunner G, Deepe GS. Complex requirements for nascent and memory immunity in pulmonary histoplasmosis. J Immunol 1999; 162: 7389-7396.